Lockup Unlocked: CoreWeave Tumbles 9% After Magnetar Sells $94.4M, Core Scientific Consideration Drops to $11.53

CoreWeave's share price took a hit after a burst of insider selling once the company's lockup window opened in August. The selling spree, which included the CEO and the largest backer, knocked the stock sharply lower on Tuesday.

CoreWeave (NASDAQ: CRWV) saw sizable disposals from big holders. Hedge fund Magnetar Financial - CoreWeave's largest shareholder - moved aggressively: on Aug. 28 it unloaded 915,339 shares for about $94.4 million and simultaneously put on a collar, buying puts with a $70 strike while writing covered calls at a $175 strike that expire on March 20, 2026. That same fund had already trimmed positions on Aug. 18 and Aug. 20, selling another 1,465,064 shares on those dates.

Inside the company, CEO Michael Intrator sold approximately 82,455 shares for roughly $7.8 million, while Chief Financial Officer Nitin Agrawal sold about 3,512 shares for roughly $335,164. Corporate secretary Kristen McVeety exited her direct stake of 311,796 shares - a sale that generated about $30 million - though she still holds 95,000 shares indirectly through a trust.

The market reacted. The stock finished Tuesday at $93.54, down about 9% for the day. That puts CRWV roughly half the level of its June high near $187, and about 38% below where it was after the company's Q2 results on Aug. 12, when management reported a bigger-than-expected loss.

Volatility was not a surprise given the math in CoreWeave's IPO paperwork: insiders controlled a large chunk of outstanding shares - the prospectus showed roughly 84% in insider hands - so analysts had warned an expiration of lockups could shake the tape.

There are knock-on consequences beyond the headline price action. CoreWeave is pursuing an all-stock acquisition of digital-infrastructure provider Core Scientific (NASDAQ: CORZ). The deal calls for 0.1235 newly issued CoreWeave shares for each Core Scientific share. When the deal was announced in July, CoreWeave was trading around $159.70, valuing the per-share consideration at about $19.72 and the transaction near $9 billion. At Tuesday's close of $93.54, that same exchange ratio would translate to roughly $11.53 per Core Scientific share - a big shift in deal economics driven purely by the change in CoreWeave's equity price.

Analysts had flagged the potential for choppiness; some still talk up the company's long-term prospects. But the immediate market picture is clear: lockup expiries unlocked a lot of supply, and big names chose to sell.

Will the pressure ease now that many insiders have had a chance to monetize, or will the stock need fresh catalysts to stabilize?